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Abstract
Intestinal Failure is a permanent loss of digestive and absorptive functions as a consequence of short
bowel syndrome and/or other primary intestinal conditions. Patients with intestinal failure (IF)
require long term parenteral nutrition to survive. The only alternative to parenteral nutrition is
intestinal transplantation which still entails high mortality. Children with intestinal failure on
parenteral nutrition may develop liver failure (LF), as a consequence of central line infections and
other conditions. In children with both irreversible IF and LF a combined transplantation is
generally considered. Despite low survival rate, combined liver/intestine transplantation is
associated to better intestinal graft survival and lower incidence and severity of rejection compared
to isolated small bowel transplantation. Recently, isolated liver transplantation was proposed in
children with IF and LF. This procedure may have a higher survival probability compared to isolated
intestinal transplant, it may allow progressive weaning from PN in children in whom the remnant
intestine has the potential for adaptation and offer a timely solution in children for whom intestinal
graft is not immediately available. This innovative approach may prove a better option compared
to combined transplantation in both the short and long term
Introduction
Primary Intestinal Failure (IF) is defined as a long term or
irreversible loss of intestinal functions. Intestinal func-
tions include digestion and absorption of nutrients,
hydroelectrolyte homeostasis and motility. The intestine
is also the major site of microflora and of the of immune
system. IF is the result of severe primary intestinal diseases
or extraintestinal diseases. The former include the short
bowel syndrome (SBS) and and other primary intestinal
conditions whose onset is often in neonatal age [1-3]. The
natural history of intestinal failure strongly depends on its
primary etiology and the management and children with
structural enterocyte effects have the worst outcome (fig-
ure 1) [4]. As a consequence of IF, Parenteral Nutrition
(PN) is required to ensure survival and growth [3,5,6].
IF may be irreversible and require life-long total or supple-
mental parenteral nutrition or may be transient and allow
a partial or total recovery of all or most of intestinal func-
tions [3]. Intestinal adaptation, defined as the functional
and structural changes of the remaining intestine, deter-
mines the chance to restore intestinal sufficiency. Gener-
ally when essential digestive functions are restored, PN is
no larger needed
Although a life-saving option, PN is associated with a
number of severe complications, including metabolic
abnormalities, catheter-related sepsis, loss of vascular
accesses and parenteral-associated cholestasis [3]. PN is
associated with substantial costs, due to the high tech
requirements and its long duration. The only alternative
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to PN is intestinal transplantation (ITx) [5-7]. Current
immunosuppressive regimens have substantially
improved the long term outcome and the international
registry for ITx reports a rapid and progressive increase in
the number of transplants performed as well as number of
centers for ITx [7]. However, ITx still entails high mortality
and substantial costs [8]and the decision to refer a child
for ITx should be based on the best prognostic evaluation
of each individual case as suggested by position paper
with the indications to ITx was produced in 2001 [9].
However, most children remain on PN, either or not
awaiting IT, and may eventually develop intestinal failure-
associated liver disease (IFALD) [9-14]. As many as 40 to
50% of the children on long-term PN eventually develop
abnormal liver function and 10% undergo liver failure
[12]. The risk of cholestasis and liver failure was strongly
reduced by the introduction of early treatment with
UDCA [15,16]. However, IFALD is, still now and in major
reference centers, a major complication of IF and a cause
of fatal events. The intestinal transplant registry reports
poor survival in children younger than 2 years because of
the rapid progression of IFALD, while awaiting appropri-
ate size-matched donor organs [17]. Combined liver and
small bowel transplantation (LSBTx) is an established life-
saving treatment option for children with SBS and pro-
gressive IFALD [15], but is loaded with substantial
mortality, problems in management and costs [18].
These evidences have forced the pediatric transplant com-
munity to reevaluate alternative options for infants with
IF and progressive IFALD and in particular in children
with SBS, the most frequent cause of IF. A feasible option
is to perform Isolated Liver Transplantation (iLTx) in a
selected group of patients with SBS and IFALD [18]. iLTx
may be considered: 1, as a an emergency life saving option
for children with end stage liver failure for which no intes-
tinal graft is available; 2, for children who are expected to
reach intestinal sufficiency and therefore would need liver
but not intestinal transplant; 3, for children who are doing
well on PN and therefore are not really candidates to
intestinal transplantation.
Discussion
The outcome of infants with SBS is associated with age-
adjusted small bowel length and function [19-22], the
rate of PN complications [12,20], and the presence of the
ileocaecal valve (ICV) and colon [3,11]. Approximately
15-20% of children with post surgery SBS and PN for
more than 4 weeks are eventually able to gain intestinal
sufficiency within 2 years (figure 1).
Long-term complications of PN regimens are considered
as major indications to ITx, and include: 1) progressive
PN-associated liver disease defined as persistence of
plasma direct bilirubin above 3 mg/dl for at least 4
months or irreversible liver disease with cirrhosis, 2)
recurrent catheter-related sepsis, defined as at least 2 cen-
tral line infections (CLIs) per year or 1 episode of fungal
sepsis or 1 major septic complication (i.e. septic shock,
multi-organ failure, metastatic abscess), 3) lack of central
venous access, and specifically the irreversible loss of 2 of
the four available standard access sites for infants and 3 of
the 6 for older children [9].
In parallel, PN has also been an area of substantial
improvement with an important reduction of major com-
plications such as micronutrient deficiencies, loss of vas-
cular accesses and central line infections [23]. The
combined progresses in PN are likely to lead to an
increased number of children with IF who will ultimately
be able to be weaned from PN.
Pharmacologic or surgical approaches to increase bowel
adaptation, such as Growth Hormone-or Epidermal
Growth Factor administration or bowel lengthening pro-
cedures, have been described and may increase the rates of
children weaned from PN [3,5,20,24-26]. Nevertheless,
enteral nutrition remains the most important prognostic
determinant for weaning from PN, as nutrients exert a
direct trophic effect on enterocytes and selective nutrients
such as lactoferrin may specifically induce enterocyte
growth and differentiation [27]. Intestinal nutrients stim-
ulate gastro-enteral secretions, promote hormonal factors,
thereby enhancing gut adaptation [3,5,20,28].
Adaptation is hampered by IFALD, namely by a combina-
tion of impaired synthetic liver function, portal hyperten-
sion, bowel wall oedema, anorexia and portal
enteropathy, all of which perpetuate PN dependence and
increase the risk for recurrent central line infections.
Combined LSBTx is nowadays considered as the standard
treatment option for IFALD. However, survival rate of
children undergoing combined LSBTx is low, with 65%
Time-related gaining of intestinal sufficiency according to the  cause Figure 1
Time-related gaining of intestinal sufficiency accord-
ing to the cause. For each group, the probability of being 
weaned from parental nutrition is reported as a time-related 
function. Each cause showed rates of intestinal sufficiency 
that were significantly different from all other causes (P < 
0.00001).Italian Journal of Pediatrics 2009, 35:28 http://www.ijponline.net/content/35/1/28
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mortality rate at 6 months [20,29-33]. Somehow surpris-
ingly compared to isolated ITx, combined transplantation
is associated to better intestinal graft survival and lower
incidence and severity of rejection [3,34,35]. In particular,
there is a lower incidence and severity of acute intestinal
graft rejection in recipients of combined transplantation
than in recipients of isolated small bowel transplantation,
probably as a consequence of immune tolerance induced
by the liver.
Recently, isolated LTx has been introduced in the manage-
ment of these patients. Initially performed as an emer-
gency procedure in patients with end stage liver failure
awaiting intestinal graft, isolated LTx may actually restore
liver sufficiency ultimately allowing a later intestinal
adaptation that may lead in selected patients to complete
enteral autonomy [30,31].
The impact of isolated liver transplantation on either sur-
vival and quality of life of patients with intestinal failure
and associated liver disease is encouraging [36-39].
Dell'Olio et al. in a recent paper reported that isolated LTx
may be life saving for selected children with SBS and
IFALD in whom the residual bowel has the potential for
intestinal adaptation [40]. The authors proposed new cri-
teria for isolated LTx in children with IFALD. In a series of
14 children receiving ILTx, 9 (64%) were alive after a
median period of 35.6 months (range 21.2-86.8) of
whom 8 were successfully weaned from parenteral nutri-
tion after a median period of 15 months. Three year sur-
vival of a parallel cohort of children who received
combined LSBTx between 1998 and 2005 was 48% [41].
In other words, if these patients would had received a
combined LSBTx rather than an isolated LTx, during the
same period of time, the majority of them would have
Table 1: Non-invasive tests for intestinal and pancreatic digestive-absorptive functions and for intestinal inflammation.
Test Normal values Implication Reference
α1-antitrypsin concentration < 0.9 mg/g increased intestinal permeability/
protein loss
Catassi C et al. J Pediatr 
1986;109:500-502
Steatocrit <2.5% (older than 2 years) fecal fat loss Guarino A et al. J Pediatr 
Gastroenterol Nutr1992;
14:268-274
Fecal reducing substances absent carbohydrate malabsorption Lindquist BL et al. Arch Dis Child 
1976;51:319-321
Elastase concentration > 200 ug/g stool exocrine pancreatic dysfunction Carroccio A et al. Gut 
1998;43:558-563
Chymotrypsin concentration > 7.5 U/g
> 375 U/24 h
exocrine pancreatic dysfunction Carroccio A et al. 
Gastroenterology 1997;
112:1839-1844
Fecal occult blood absent fecal blood loss, distal intestinal 
inflammation
Fine KD. N Engl J Med 
1996;334:1163-1167
Calprotectin concentration 100 ug/g intestinal inflammation Fagerberg UL et al. J Pediatr 
Gastroenterol Nutr 2003;
37:468-72
Fecal leukocytes < 5/microscopic field colonic inflammation Harris JC et al. 1972;76:697-703
Nitric oxide in rectal dyalisate < 5 uM of NO2
-/NO3
- rectal inflammation Berni Canani R et al. Am J 
Gastroenterol 2002;97:1574-1576
Dual sugar (cellobiose/mannitol) 
absorption test
Urine excretion ratio: 0.010+0.018 Increased intestinal permeability Catassi C, et al. J. Pediatr Gastro 
Nutr 2008;46:41-47
Xylose oral load 25 mg % Absorptive surface Craig RM, Ehrenpreis ED J Clin 
Gastroenterol 1999; 29:143-50
Iron absorption test Based on percentile reference De Vizia et al. J. Pediatri 
Gastroentrol Nutr. 1992;14-21-6Italian Journal of Pediatrics 2009, 35:28 http://www.ijponline.net/content/35/1/28
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died. This data raise the option of performing isolated LTx
rather than combined LSBTX in children doing well on
PN.
On the basis of their experience, Dell'Olio et al. proposed
the following modifications to their own original criteria
for isolated LTx to the following: 1. established IFALD
(serum bilirubin >200 mmol/L, moderate/severe fibrosis,
portal hypertension); 2. at least 50 cm functional small
bowel remaining intact in the absence of ICV or 30 cm
with ICV; 3. at least 50% of the estimated daily energy
requirement was tolerated as enteral feeds, for at least 4
weeks before the development of liver disease and was
associated with an increase in weight; 4. children with
dilated and dysmotile bowel who had minimal line infec-
tions (<6 in 12 months).
It is clear that length of residual bowel play a significant
role in predicting whether intestinal failure may be revers-
ible. However function is more important than length
oral may be assessed by gradually decreasing parenteral
nutrition and increasing oral intake in parallel. There is no
scheme to do that and the task is not easily achieved.
However intestinal function tests may be used to non
invasively monitor intestinal function, thereby providing
information on time related adaptation and guiding pro-
gressive weaning. A list of intestinal function test and their
interpretation is provided in table 1. [42]
Intestinal digestive-absorptive processes may improve fol-
lowing isolated LTx because portal hypertension and
bowel oedema could have contributed to intolerance to
enteral feeds in the pretransplant phase [18,43].
In patients with severe motility impairment or nutrient
malabsorption, full adaptation is unlikely, and the chance
of weaning is low. In these patients either long term PN or
combined LSBTX should be considered. Finally a compli-
cations is the relatively high risk of food allergy, that com-
plicates evaluation of tolerance
The success of isolated LTx is limited by frequent postop-
erative complications The rates of infectious, vascular, bil-
iary, and surgical complications are higher compared with
patients undergoing liver transplants for other indications
[18].
A potential problem of patients with intestinal failure
receiving isolated LTx could be antirejection drugs malb-
sorption but it has been reported that therapeutic levels of
these drugs may be achieved in these patients in the post-
operative period [44].
A major problem of iLT in patients with IF is its cost. The
high rates of post-operative complications contribute to
high costs, as do extended hospital and intensive care unit
stay. PN administration also increases the already heavy
post-transplantation charges. These costs need to be bal-
anced against the cost of complications and hospitaliza-
tions for patients on the waiting list for combined LSBTX.
As these patients may ultimately skip intestinal transplan-
tation, improving long-term outcomes and survival, the
cost on the front end may well be justified [43,45].
Conclusion
In IF therapeutic options are complex, and not well
defined and yet they are potentially crucial for patient sur-
vival and associated with high costs. The therapeutic strat-
egy impact on quality of life is correspondingly high.
Long term data on the history of patients with IF and LF
treated with different approaches should be obtained to
better define when isolated LTx vs combined transplanta-
tion should be used for IFALD,. This is hampered by the
low number of patients, their scattered clinical conditions
and the rapid progresses that are being made in various
areas of IF including clinical nutrition, growth factors,
microflora modulation and central line management. On
the other side, there are substantial progresses in either
surgery and immune suppression. These progresses are
likely to open new hopes for children that only few years
ago in rich Countries - and now also in less rich Countries-
are admitted for IF.
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